

# Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



23<sup>rd</sup> May, 2022

To,  
The Manager,  
Department of Corporate Relations,  
BSE Limited,  
P J Towers, Dalal Street,  
Fort, Mumbai- 400001.

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra(E), Mumbai- 400051.

Dear Sir,

**Subject:** Intimation to Stock Exchanges under Regulation 30 of the Securities and Exchange Board of India (listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

## **Outcome of Board Meeting**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ["SEBI LODR Regulations"], we wish to inform the following outcome of the meeting of the Board of Directors held today, i.e. 23<sup>rd</sup> May, 2022:

- (a) The audited financial results for the quarter and Year ended 31<sup>st</sup> March, 2022 along with the Auditor's Report thereon (Enclosed herewith) have been adopted by the Board.

Kindly note that the meeting was commenced at 11.30 AM and concluded at 3.00 PM

You are requested to take note of the above.

Thanking You,  
Yours Faithfully,

For Krebs Biochemicals & Industries Limited


Taruni Banda  
Company Secretary

Regd. Office : Kothapalli (V), Kasimkota (M), Anakapalli, Visakhapatnam, Andhra Pradesh-531 031 Corporate Office :  
8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-S00 03  
Tel : 040-66808040 E-mail marketing@krebbsbiochem.com Website -www.krebbsbiochem.com

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Vlsakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034


**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022**

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Year Ended	
		31.03.2022 (Audited)	31.12.2021 (Un Audited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)
	<b>PART - 1</b>					
1	Revenue from Operations					
	a) Net Sales / Income from Operations	1,780.49	1,809.47	1,307.42	5,294.06	3,860.64
	b) Other Operating Income	135.26	371.53	278.51	676.25	1,509.40
2	Other Income	79.28	20.13	44.41	115.58	62.13
3	<b>Total Income from operations (1+2)</b>	<b>1,995.03</b>	<b>2,201.13</b>	<b>1,630.34</b>	<b>6,085.89</b>	<b>5,432.17</b>
4	Expenses					
	a) Cost of Material Consumed	1,599.10	1,641.78	603.67	4,618.01	2,562.26
	b) Changes in Inventories of Finished goods, Work-In-Progress	(179.41)	(86.80)	290.50	(553.79)	32.49
	c) Employee Benefits Expenses	443.47	419.96	402.30	1,530.02	1,582.78
	d) Finance Costs	27.97	182.34	149.32	539.10	627.90
	e) Depreciation and Amortisation Expense	204.87	141.60	141.34	629.67	512.40
	f) Other Manufacturing Expenses	893.99	1,024.76	646.12	3,305.78	2,628.48
	g) Other Expenses	136.43	171.57	95.75	469.78	321.72
	<b>Total Expenses (4)</b>	<b>3,126.42</b>	<b>3,495.22</b>	<b>2,329.00</b>	<b>10,538.57</b>	<b>8,268.03</b>
5	<b>Profit / (Loss) before exceptional items and tax (3±4)</b>	<b>(1,131.39)</b>	<b>(1,294.09)</b>	<b>(698.66)</b>	<b>(4,452.68)</b>	<b>(2,835.86)</b>
6	Exceptional Items:	-	-	-	-	-
7	<b>Profit / (Loss) before Tax (5 ± 6)</b>	<b>(1,131.39)</b>	<b>(1,294.09)</b>	<b>(698.66)</b>	<b>(4,452.68)</b>	<b>(2,835.86)</b>
8	Tax Expense					
	a) Current Tax	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-
9	<b>Profit / (Loss) for the period (7 ± 8)</b>	<b>(1,131.39)</b>	<b>(1,294.09)</b>	<b>(698.66)</b>	<b>(4,452.68)</b>	<b>(2,835.86)</b>
10	Other Comprehensive Income (OCI)					
i	Items that will not be reclassified to profit or Loss	-	-	25.51	-	25.51
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-
iii	Items that will be reclassified to profit or Loss	(30.48)	-	(8.25)	(34.65)	(8.25)
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-	-
	<b>Total Other Comprehensive Income (Net of Tax)</b>	<b>(30.48)</b>	<b>-</b>	<b>17.26</b>	<b>(34.65)</b>	<b>17.26</b>
11	<b>Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)</b>	<b>(1,161.86)</b>	<b>(1,294.09)</b>	<b>(681.40)</b>	<b>(4,487.33)</b>	<b>(2,818.60)</b>
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	2,156.06	2,156.06	1,962.06	2,156.06	1,962.06
13	Other Equity excluding Revaluation Reserve	-	-	-	(10,770.47)	(7,340.43)
14	Earning Per Share (of Rs.10/- each) (not Annualised)					
	a) Basic	(5.39)	(6.00)	(3.47)	(20.81)	(14.37)
	b) Diluted	(5.39)	(6.00)	(3.47)	(20.81)	(14.37)
15	<b>Net Worth (including Retained Earnings)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(7,509.32)</b>	<b>(4,273.29)</b>

See accompanying notes to the Financial results

- The above results have been reviewed by the Audit Committee at its meeting held on 21st May, 2022 and approved by the Board of Directors of the Company at its meeting held on 23rd May, 2022.
- The Company is operating in one segment only hence no segment results have been disclosed.
- The figures for quarter ended 31st March 2022 and 31st March 2021 are the balancing figures between the audited figures for the full financial year and the reviewed year-to-date figures up to the third quarter of the respective financial years. Figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.
- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.
- The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of these assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given the uncertainties associated with its nature and duration. The company will continue to monitor any material changes to future economic conditions.

  
 Pabitrakumar Kalipada Bhattacharyya  
 Managing Director  
 DIN :07131152

Place: Mumbai  
Date: 23.05.2022

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

Cash Flow Statement for the year ended 31.03.2022

(Rs. In Lacs)

Particulars	Year ended 31.03.2022	Year Ended 31.03.2021
<b>Cash Flow from Operating Activities</b>		
Net Profit before tax and exceptional items	(4,452.68)	(2,835.86)
<b>Adjustments for:</b>		
Depreciation and Amortisation Expenses	629.67	512.40
Non Current provisions	(27.65)	27.31
Financial Charges	539.10	627.90
<b>Operating Profit before Working Capital Changes</b>	<b>(3,311.56)</b>	<b>(1,668.25)</b>
<b>Changes in Working Capital</b>		
(Increase)/Decrease in Inventories	(896.22)	(160.49)
(Increase)/Decrease in Trade Receivables	(57.67)	(9.77)
(Increase)/Decrease in Other Financial Assets	15.59	(28.50)
(Increase)/Decrease in Other Current Assets	(530.28)	(3.37)
(Increase)/Decrease in Financial Assets	(5.58)	(70.64)
(Increase)/Decrease in Other Non Current Assets	76.96	(177.35)
Increase /(Decrease) in Retirement benefit obligations	(9.46)	(48.15)
Increase/(Decrease) in Current Provisions	(23.38)	(1.10)
Increase/(Decrease) in Trade Payables	1,712.97	(187.13)
Increase/(Decrease) in Other financial liabilities	531.78	1,061.36
Increase/(Decrease) in financial liabilities	(1.38)	-
Increase/(Decrease) in Other Current Liabilities	776.63	(164.09)
<b>Cash generated from Operations</b>	<b>1,589.95</b>	<b>210.78</b>
<b>Net Cash Flow from Operating Activities</b>	<b>(1,721.61)</b>	<b>(1,457.48)</b>
Proceeds from / (Payment to) Capital Work-in-Progress	355.83	(774.35)
Proceeds from / (Payment to) Property, Plant & Equipment	(2,707.84)	(1,776.29)
Proceeds from / (Payment to) Other Financial Liabilities	62.06	295.71
<b>Cash Flow from Investing Activities</b>	<b>(2,289.95)</b>	<b>(2,254.93)</b>
Financial Charges	(539.10)	(627.90)
Proceeds from / (Payment to) borrowings	3,238.35	3,349.06
Proceeds from / (Payment to) Share Capital	1,251.30	1,044.89
<b>Cash Flow from Financing Activities</b>	<b>3,950.55</b>	<b>3,766.05</b>
<b>Net Increase (Decrease) in Cash and Cash equivalents</b>	<b>(61.01)</b>	<b>53.64</b>
Cash and Cash equivalents as at the beginning of the year	71.07	17.43
<b>Cash and Cash equivalents at the end of the year</b>	<b>10.06</b>	<b>71.07</b>



Pabitrakumar Kalipada Bhattacharyya

Managing Director

DIN :07131152

Place: Mumbai


Date: 23.05.2022

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**  
CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031  
Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

**Statement of Assets and Liabilities**

Rs. In Lacs

Particulars	As at 31.03.2022 Audited	As at 31.03.2021 Audited
<b>ASSETS</b>		
<b>Non Current Assets</b>		
(a)Property, Plant and Equipment	13,768.51	11,626.49
(b)Capital Work in Progress	653.09	1,008.91
(c)Other Intangible Assets	102.38	166.24
(d)Intangible assets under development	184.71	184.71
(e)Financial Assets	229.88	224.30
(f)Other Non Current Assets	492.67	569.62
<b>Total Non Current Assets</b>	<b>15,431.24</b>	<b>13,780.27</b>
<b>Current Assets</b>		
(a)Inventories	2,556.26	1,660.04
(b)Financial Assets		
(i) Trade Receivables	87.65	29.98
(ii) Cash & Cash Equivalents	10.06	71.07
(iii) Other Financial Assets	21.08	36.67
(c)Other Current Assets	874.28	344.00
<b>Total Current Assets</b>	<b>3,549.33</b>	<b>2,141.76</b>
<b>Total Assets</b>	<b>18,980.57</b>	<b>15,922.03</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a)Equity Share Capital	2,156.06	1,962.06
(b)Other Equity	(9,665.38)	(6,235.35)
<b>Total Equity</b>	<b>(7,509.32)</b>	<b>(4,273.29)</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
(a)Financial Liabilities		
(i)Long Term Borrowings	13,293.00	10,054.64
(ii)Other Financial Liabilities	627.13	565.07
(b)Provisions	30.16	50.09
(c)Retirement benefit obligations	233.20	206.28
(d)Other Non Current Liabilities	4,500.00	4,500.00
<b>Total Non Current Liabilities</b>	<b>18,683.49</b>	<b>15,376.08</b>
<b>Current Liabilities</b>		
(a)Financial Liabilities		
(i)Short Term Borrowings	998.62	1,000.00
(ii)Trade Payables		
(a) Total outstanding dues of micro and small enterprises	681.76	260.46
(b) Total outstanding dues of creditors other than micro and small enterprises	3,108.88	1,817.21
(iii)Other Financial Liabilities	1,419.89	888.10
(b)Other Current Liabilities	1,480.72	704.09
(c)Provisions	59.07	82.45
(d)Retirement benefit obligations	57.46	66.92
<b>Total Current Liabilities</b>	<b>7,806.40</b>	<b>4,819.24</b>
<b>Total Equity and Liabilities</b>	<b>18,980.57</b>	<b>15,922.03</b>
 Pabitrakumar Kalipada Bhattacharyya Managing Director DIN :07131152		
Place: Mumbai Date: 23.05.2022		

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**  
CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandai, Anapakalli, Visakhapatnam, Andhra Pradesh - 531 031  
Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

Additional disclosures as per Regulation 52(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Sl No	Particulars	As at 31-03-2022		As at 31-03-2021	
1	Debt-equity ratio [no.of times]*	(1.91)		(2.60)	
2	i) Last due date for the payment of dividend of Non-convertible Redeemable preference shares (NCRPS)				
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA		NA	
	b) 9% Non-Convertible Redeemable Preference Shares (Issued on 30-12-2021)	NA		NA	
	ii) Whether Dividend has been paid on due dates	NA		NA	
3	i) Last due date for the repayment of principal of NCRPS	NA		NA	
	ii) Whether principal has been repaid on due dates	NA		NA	
4	Next due date and amount for payment of dividend of NCRPS	(Rs.Lacs)	Date	(Rs.Lacs)	Date
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA	NA	NA	NA
	b) 9% Non-Convertible Redeemable Preference Shares (Issued on 30-12-2021)	NA	NA	NA	NA
5	Next due date and amount for the repayment of principal of NCRPS (falling due within next one year period)				
	a) 9% Non-Convertible Redeemable Preference Shares (Issued on 05-02-2020)	NA	NA	NA	NA
	b) 9% Non-Convertible Redeemable Preference Shares (Issued on 30-12-2021)	NA	NA	NA	NA
6	Next due date and amount for the repayment of principal of CPs (falling due within next one year period)	NA	NA	NA	NA
	Particulars	As at 31-03-2022		As at 31-03-2021	
		(Rs.Lacs)		(Rs.Lacs)	
7	Debt Service Coverage ratio **	(0.22)		(0.14)	
8	Interest Service coverage ratio ***	(7.26)		(3.52)	
9	Outstanding redeemable preference shares (quantity and value)				
	Quantity	130.00		30.00	
	Value	13,000.00		3,000.00	
10	Capital redemption reserve/debenture redemption reserve	-		-	
11	Net Worth****	(8,653.79)		(5,417.76)	
12	Net Profit/( Loss) after tax (Including Other comprehensive Income)	(4,487.32)		(2,818.60)	
13	Earning per share	(20.81)		(14.37)	

**Note:**

- 1 \* Debt-Equity Ratio = Total Borrowings divided by Equity
- 2 \*\* DSCR = EBITDA (Earnings before Interest, Tax, depreciation and Amortization) divided by (Interest expenses & principal amount on Short & Long Term borrowings)
- 3 \*\*\* ISCR = Profit before interest and exceptional items divided by interest expense
- 4 \*\*\*\* Net worth as per section 2(57) of Companies Act, 2013 (aggregate value of the paid-up share capital and all reserves created out of the profits and securities premium account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, as per the audited balance sheet, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation).
- 5 The above results have been reviewed by the Audit Committee at its meeting held on 21st May, 2022 and approved by the Board of Directors of the Company at its meeting held on 23rd May, 2022.

Place:Mumbai  
Date:23.05.2022

  
Pabitrakumar Kalipada Bhattacharyya  
Managing Director  
DIN :07131152

Date:23-05-2022

To,  
The Manager,  
Department of Corporate Relations,  
BSE Limited,  
P J Towers, Dalal Street,  
Fort, Mumbai- 400001.

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,  
Sub: Declaration Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for unmodified opinion

**DECLARATION FOR UNMODIFIED OPINION**

We hereby declare that, the Statutory Auditors of the Company M/s Bhavani & Co., Chartered Accountants, (Firm Reg No.012139S) have issued an Audit Report with unmodified opinion on Standalone Financial Results for the quarter & year ended 31st March 2022.

Yours Faithfully,  
For Krebs Biochemicals & Industries Limited



Pabitra Kumar Kalipada Bhattacharya

Managing Director



**INDEPENDENT AUDITORS' REPORT ON THE QUARTERLY AND YEAR TO DATE AUDITED FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED**

**TO THE BOARD OF DIRECTORS OF KREBS BIOCHEMICALS AND INDUSTRIES LIMITED**

**Report on the Audit of Financial Results**

**Opinion**

We have audited the accompanying standalone financial results of Krebs Biochemicals and Industries Limited ("the Company") for the quarter ended 31<sup>st</sup> March, 2022 and the year to date results for the period from 1<sup>st</sup> April, 2021 to 31<sup>st</sup> March, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us the Statement:

(a) are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

(b) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards (Ind AS) and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended 31<sup>st</sup> March, 2022 as well as the year to date results for the period from 1<sup>st</sup> April, 2021 to 31<sup>st</sup> March, 2022.

**Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the '*Auditor's Responsibilities for the Audit of the Standalone Financial Results*' section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in



accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the annual standalone financial statements for the year ended 31<sup>st</sup> March, 2022. The Company's Board of Directors are responsible for the preparation and presentation of these standalone financial results that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.



## **Auditor's Responsibilities for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial results. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of standalone financial statements on whether the company has adequate internal financial controls with reference to standalone financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If



we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern

- Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related.

**Place : Hyderabad**  
**Date : 23-05-2022**

**For BHAVANI & Co.**  
**Chartered Accountants**  
**Firm Reg. No:012139S**

KAVITHA  
PADMINI  
SIRIGINA

Digitally signed  
by KAVITHA  
PADMINI  
SIRIGINA

**(CA S KAVITHA PADMINI)**  
**PARTNER**  
**M.No : 229966**

**UDIN : 22229966AJKTZV9527**